WO2001016577A1 - Procede de determination d'analytes au moyen d'un spectre en proche infrarouge, d'un spectre visible adjacent et de longueurs d'ondes distinctes de spectre en proche infrarouge - Google Patents

Procede de determination d'analytes au moyen d'un spectre en proche infrarouge, d'un spectre visible adjacent et de longueurs d'ondes distinctes de spectre en proche infrarouge Download PDF

Info

Publication number
WO2001016577A1
WO2001016577A1 PCT/CA2000/001000 CA0001000W WO0116577A1 WO 2001016577 A1 WO2001016577 A1 WO 2001016577A1 CA 0001000 W CA0001000 W CA 0001000W WO 0116577 A1 WO0116577 A1 WO 0116577A1
Authority
WO
WIPO (PCT)
Prior art keywords
radiation
measurements
discrete
wavelengths
nir region
Prior art date
Application number
PCT/CA2000/001000
Other languages
English (en)
Inventor
Thomas G. Scecina
Romuald Pawluczyk
Theodore E. Cadell
Original Assignee
Cme Telemetrix Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cme Telemetrix Inc. filed Critical Cme Telemetrix Inc.
Priority to JP2001520083A priority Critical patent/JP2003508744A/ja
Priority to EP00955994A priority patent/EP1214577A1/fr
Priority to CA002383725A priority patent/CA2383725A1/fr
Priority to US10/070,187 priority patent/US6741876B1/en
Publication of WO2001016577A1 publication Critical patent/WO2001016577A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/145—Measuring characteristics of blood in vivo, e.g. gas concentration, pH value; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid, cerebral tissue
    • A61B5/1455—Measuring characteristics of blood in vivo, e.g. gas concentration, pH value; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid, cerebral tissue using optical sensors, e.g. spectral photometrical oximeters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/145—Measuring characteristics of blood in vivo, e.g. gas concentration, pH value; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid, cerebral tissue
    • A61B5/14532—Measuring characteristics of blood in vivo, e.g. gas concentration, pH value; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid, cerebral tissue for measuring glucose, e.g. by tissue impedance measurement
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/145—Measuring characteristics of blood in vivo, e.g. gas concentration, pH value; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid, cerebral tissue
    • A61B5/14546—Measuring characteristics of blood in vivo, e.g. gas concentration, pH value; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid, cerebral tissue for measuring analytes not otherwise provided for, e.g. ions, cytochromes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N21/00—Investigating or analysing materials by the use of optical means, i.e. using sub-millimetre waves, infrared, visible or ultraviolet light
    • G01N21/17—Systems in which incident light is modified in accordance with the properties of the material investigated
    • G01N21/25—Colour; Spectral properties, i.e. comparison of effect of material on the light at two or more different wavelengths or wavelength bands
    • G01N21/31—Investigating relative effect of material at wavelengths characteristic of specific elements or molecules, e.g. atomic absorption spectrometry
    • G01N21/314—Investigating relative effect of material at wavelengths characteristic of specific elements or molecules, e.g. atomic absorption spectrometry with comparison of measurements at specific and non-specific wavelengths
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N21/00—Investigating or analysing materials by the use of optical means, i.e. using sub-millimetre waves, infrared, visible or ultraviolet light
    • G01N21/17—Systems in which incident light is modified in accordance with the properties of the material investigated
    • G01N21/25—Colour; Spectral properties, i.e. comparison of effect of material on the light at two or more different wavelengths or wavelength bands
    • G01N21/31—Investigating relative effect of material at wavelengths characteristic of specific elements or molecules, e.g. atomic absorption spectrometry
    • G01N21/35—Investigating relative effect of material at wavelengths characteristic of specific elements or molecules, e.g. atomic absorption spectrometry using infrared light
    • G01N21/359—Investigating relative effect of material at wavelengths characteristic of specific elements or molecules, e.g. atomic absorption spectrometry using infrared light using near infrared light

Definitions

  • FIELD OF INVENTION This invention relates to a non-invasive device and method for monitoring concentration levels of blood constituents in living subjects such as humans or animals, using a full spectrum of the near infrared portion of the light spectrum and adjacent visible spectrum in addition to discrete longer wavelengths of the near infrared region of the light spectrum.
  • Invasive techniques of measuring blood constituents are in common usage. These techniques are painful, potentially dangerous and expensive to operate. A typical procedure is to obtain a blood sample from a vein and this sample is then tested in a medical laboratory, using a number of chemical procedures to measure each constituent separately. Alternatively, home glucose testing uses a finger puncture that is spotted onto an enzyme-based semi-permeable membrane test strip and is allowed to react for a certain length of time, with insulin administration then based upon either a visual colour comparison with a standard colour chart or by means of a more accurate and unambiguous spectroscopic technique (for example reflectance). There is a risk of infection and sometimes a patient can develop a rash when these invasive techniques are used.
  • Non-Invasive Techniques are painful, potentially dangerous and expensive to operate.
  • Previous devices for non-invasively monitoring concentration of blood constituents of a patient are known.
  • a sensor is used to externally measure either the concentration of the constituent in gases emitted by the body; the concentration contained in perspiration; or the concentration contained in body fluids such as tears, saliva or urine samples.
  • An example of this approach is the GlucoWatch, developed by Cygnus. It draws interstitial fluid from a body part onto a patch and measures the glucose in that fluid. This approach is not ideal in that the patch causes irritation and each patch, which last for 12 hours, needs to be calibrated using a reference method which requires an invasive finger stick to obtain a blood sample.
  • the blood constituent is measured using radiation passed through a part of the patient's body such as the earlobe or reflected from a body part such as a finger or forearm.
  • some have a radiation source which emits light in one wavelength only or two wavelengths (see for example US 4,655,225; US 4,883,953; and US 4,882,492); other previous devices have more than one light source but have only a limited number of measuring wavelengths (U.S. Patents Nos. 4,915,827; 5,028,787; 5,077,476; 5,237,178; 5,319,200 and 5,438,201)].
  • Some of the methods that measure a limited number of wavelengths utilize the 1100 to 1700 nm region because of sharper analyte spectra that exist in this region. Others measure at wavelengths in the 600 to llOOnm region. These methods provide information relating to the analyte of interest, but fail to provide sufficient independent information about other analytes whose absorption interferes with the desired analyte.
  • Some previous devices which take measurements in earlobes do not take into account changes in the thickness of a patient's earlobes compared to that of other patients or the change in size of a patient's earlobes or the change in the transmission path length due to the pulsing of blood through the patient; or, they do not take into account temperature variations in the earlobes from patient to patient, or, the results fluctuate with prolonged operation.
  • the present invention provides a method for monitoring the concentration level of a particular constituent or, alternatively, of measuring the concentration level of more than one different constituents in a non-invasive device, the method producing result(s) in a short time period that is /are accurate and reliable.
  • the present inventors have determined that measurement at a continuum of wavelengths from 500 to llOOnm provides information about the concentration of the desired analyte and very importantly further information about the many other analytes that interfere with an accurate measurement
  • the inventors have discovered that analyte measurement accuracy is enhanced by adding a limited number of discrete wavelength measurements in the 1100 to 1700nm region to a full spectra absorption measurement of a continuum of wavelengths in the 500 to llOOnm regionUsing this combination it is possible to gain a significant improvement in analyte measurement accuracy.
  • the 500-1100 run region is referred to as the "AV and NIR region” while the 1100-1700 nm region is referred to as the "longer wavelength NIR region” or "LWNIR".
  • measurement of discrete wavelengths is at a sufficiently high signal to noise ratio in order to achieve desired results.
  • the present invention provides a method for monitoring the concentration level of a constituent in tissue comprising placing the tissue in a non-invasive device capable of emitting radiation; directing the radiation onto the tissue; measuring radiation collected from the tissue; calculating the concentration level based on the measured radiation wherein the radiation directed onto the tissue and collected from the tissue is of a continuum of wavelengths in the 500-1 lOOnm range, and discrete wavelengths in the range from 1100 to 1700nm.
  • the present invention provides a method for measuring concentration levels of blood constituents within a living subject such as humans or animals wherein, in respect of the AV and NIR region, there is used a polychromatic light source or other radiation source that emits a broad spectrum of light in the range from 500nm to llOOnm.
  • the method comprises the steps of directing light at a continuum of wavelengths simultaneously onto a bodypart of a subject; collecting the continuum of light after the light has been directed onto the part; focusing the collected light onto a grating, dispersing the continuum of light into a dispersed spectrum of component wavelengths of the collected light onto a linear array detector, the linear array detector taking measurements of at least one of transmitted and reflected light from the collected light in adjacent visible spectrum, and near infrared range from 500-1100 region, and the measurements are transferred to a microprocessor.
  • the method comprises the steps of directing one or more narrow band sources of light on the body part, collecting the one or more narrow bands on one or more detectors (depending on the specific configuration chosen), these measurements are also transferred to the microprocessor.
  • the microprocessor uses these measurements and a calibration algorithm to calculate the concentration level of said at least one constituent of said blood and tissue.
  • a method for determining a concentration of a constituent in a tissue of a subject comprising the steps of: irradiating the tissue with a broad spectrum of radiation in the AV and NIR region; irradiating the tissue with radiation in the longer wavelength NIR region; measuring at least one of transmitted or reflected radiation from the tissue at a continuum of wavelengths in the AV and NIR region and at one or more discrete wavelengths in the longer wavelength NIR region; and calculating the concentration of the constituent on the basis of the measurements, thereby determining the concentration of the constituent in the tissue.
  • the continuum of wavelengths from the AV and NIR region is between 500 and 1100 nm.
  • the discrete wavelength in the longer wavelength NIR region is between 1100 and 1700 nm.
  • one or more discrete wavelengths are between 1100 and 1300 nm.
  • one or more discrete wavelengths is between 1590 and 1700 nm.
  • At least two discrete wavelengths are measured at least one of which is between 1100 and 1300 nm and at least one of which is betweenl590 and 1700 nm.
  • the discrete wavelength measurements are at 1150, 1195, 1215, 1230, 1240 and 1250 nm.
  • the discrete wavelength measurements are at 1595, 1610 and 1620 nm. According to another embodiment, the discrete wavelength measurements are at 1150, 1195, 1215, 1230, 1240, and 1250 nm. , and at 1595, 1610 and 1620 nm.
  • the radiation at each discrete wavelength is provided by a separate energy source. According to another embodiment, the radiation at each of the discrete wavelengths is provided sequentially.
  • the radiation at all of the discrete wavelengths is provided simultaneously.
  • a single energy source provides continuous energy over the radiation range of 1100 to 1300nm.
  • a single energy source provides continuous energy over the radiation range of 1140 to 1260nm.
  • a single energy source provides radiation in the range of 500 to 1300nm.
  • the steps of irradiating the tissue in the AV and NIR region, and in the longer wavelength NIR region are done simultaneously, and the measurement in each of said AV and NIR region and said longer wavelength NIR region is made simultaneously.
  • a method for measuring concentration of a blood constituent within a body part of a living subject comprising: irradiating a body part of the subject with a broad spectrum of radiation in the AV and NIR region; collecting the radiation from the AV and NIR region after the radiation has been directed onto the part; dispersing the collected radiation into a dispersed spectrum of component wavelengths onto a detector, the detector taking measurements of at least one of transmitted and reflected radiation from the collected radiation; transferring the measurements to a processor; irradiating the body part of the subject with radiation in the longer wavelength NIR region; detecting one or more discrete wavelengths in the longer wavelength NIR region after the radiation has been directed onto the part, the detector taking measurements of at least one of transmitted and reflected radiation ; and transferring the measurements to a processor; based on the measurements and one or more calibration algorithms, the processor calculating the concentration of said constituent of said blood.
  • the detector is a linear array detector and the measurement is of absorbed radiation.
  • the continuum o f wavelengths from the AV and NIR region is between 500 and 1 100 nm.
  • the discrete wavelength in the longer wavelength NIR region is between 1100 and 1700 nm.
  • the one or more discrete wavelengths are between 1100 and 1300 nm.
  • the one or more discrete wavelengths is between 1590 and 1700 nm.
  • At least two discrete wavelengths are measured at least one of which is between 1100 and
  • the discrete wavelength measurements are at 1150, 1195, 1215, 1230, 1240 and 1250 nm.
  • the discrete wavelength measurements are at 1595, 1610 and 1620 nm. According to another embodiment, the discrete wavelength measurements are at 1150, 1195, 1215, 1230, 1240, and 1250 nm. , and at 1595, 1610 and 1620 nm.
  • a method for measuring concentration of a blood constituent within a body part of a living subject comprising: irradiating the body part of the subject with a first continuum of a broad spectrum band of radiation in the AV and NIR region; collecting the first band of radiation after the radiation has been directed onto the part; dispersing the continuum of collected radiation into a dispersed spectrum of component wavelengths onto a detector, the detector taking measurements of at least one of transmitted and reflected radiation from the collected radiation; and transferring the measurements to a processor; irradiating the body part of the subject with a second continuum of a radiation band in the longer wave NIR region; collecting the second band of radiation after the radiation has been directed onto the part; dispersing the continuum of collected radiation into a dispersed spectrum of component wavelengths onto a detector; detecting one or more discrete wavelengths in the longer wavelength NIR region; the detector taking measurements of at least one of transmitted and reflected radiation from the collected radiation; and transferring the measurements to a
  • the discrete wavelength in the longer wavelength NIR region is between 1100 and 1700 nm. According to another embodiment, the one or more discrete wavelengths are between 1100 and 1300 nm.
  • the one or more discrete wavelengths is between 1590 and 1700 nm.
  • At least two discrete wavelengths are measured at least one of which is between 1100 and 1300 nm and at least one of which is betweenl590 and 1700 nm.
  • the discrete wavelength measurements are at 1150, 1195, 1215, 1230, 1240 and 1250 nm.
  • the discrete wavelength measurements are at 1595, 1610 and 1620 nm.
  • the discrete wavelength measurements are at 1150, 1195, 1215, 1230, 1240, and 1250 nm. , and at
  • the subject is a human and the body part is a finger.
  • the constituent is glucose
  • the tissue is blood.
  • a second source of radiation is provided for discrete wavelengths.
  • Figure 1 shows absorbance spectra from 500-1380 nm for globulins, glucose, urea, creatine, cholesterol and human serum albumin with water displacement compensation; and
  • Figure 2 is a graph showing improvement in glucose prediction in relation to absorbance error in the measurement at the discrete longer NIR wavelengths.
  • Figure 3 is a diagram illustrating one embodiment of the present invention, multiple narrow band light sources, sequentially energized, and a single detector.
  • Figure 4 is a diagram illustrating another embodiment of the present invention providing multiple narrow band light sources, simultaneously energized, and multiple detectors.
  • Figure 5 is a diagram illustrating a further embodiment of the present invention which comprises a feasibility model of a system for determining the concentration of a constituent.
  • carbohydrates means a substance, or analyte found in a tissue and includes carbohydrates such as for example glucose, bilirubin, a protein, for examples albumin or , hemoglobin.
  • in a solution means in a liquid environment such as, for examples interstitial, or other bodily fluid
  • tissue means any tissue of the body of a subject including for example, blood, extracellular spaces, and can mean the entire composition of a body part such as a finger or ear lobe.
  • subject means any member of the animal kingdom including, preferably, humans.
  • the present inventors have determined that in order to improve the ability to measure analytes in the tissue of a subject using a non-invasive device using spectral data, it is only necessary to add a limited number of discrete wavelength measurements in the longer wavelength NIR region to a full spectra absorption measurement at a continuum of wavelengths in the 500 to llOOnm region to gain a significant improvement in analyte measurement accuracy.
  • analyte measurement accuracy achieved through previous methods is enhanced by adding a limited number of discrete wavelength measurements in the 1100 to 1300nm (the "First region") and 1590 to 1700nm (the "Second region”) region to a full spectra absorption measurement in the 500 to llOOnm region to gain a significant improvement in analyte measurement accuracy.
  • wavelengths in the First region are 1150, 1195, 1215, 1230, 1240 and 1250 nm.
  • a significant improvement can be made by adding only those wavelengths in the First region.
  • adding wavelengths in the Second region, preferably 1595, 1610 and 1620, can further enhance accuracy.
  • the method of the present invention provides for measurements of a body part to be taken in the AV and NIR region and added to measurements taken in either the First region or the First and Second regions. It will be readily appreciated that the method includes addition of measurements in all three regions and that the measurements may be taken simultaneously or sequentially.
  • the 580 to llOOnm range has been used because, among other reasons, silicon detectors are sensitive in that range. Silicon detectors, particularly silicon-based detector arrays provide superior noise and dynamic range performance, are readily available, and, are relatively inexpensive. However, the 900 to 1700nm wavelength range provides sharper spectra for many of the analytes of interest as may be seen by referring to Figure 1.
  • An Indium Gallium Arsenite (InGaAs) detector arrays are typically used to measure spectra in this region. These provide inferior noise and dynamic range performance to silicon. Thus the lower signal to noise ratio offsets some of the advantage of the sharper spectra.
  • Other detector arrays may also be used in these First and Second regions.
  • narrow band light is used to illuminate the tissue. Since the amount of light energy that can be delivered to the finger is limited by safety considerations, narrow band illumination allows a much higher intensity of light in a specific band, lOnm for example, than can be utilized with a wideband source. This means that more light power for each wavelength can be delivered to the detector and thus makes it easier to achieve a high signal to noise ratio. As one skilled in the art will readily appreciate one approach would be to illuminate the finger sequentially at a high enough rate to sufficiently reduce errors from short term absorption changes in the finger due to the heart beat pulse and other effects. This approach is illustrated in Figure 3.
  • the illumination sources (10) for a device of the invention can be any source of narrow band light with sufficient power, wavelength stability and consistency and amplitude stability.
  • Examples of such devices are diode lasers, LEDs, LEDs with a filter associated with each LED to provide more narrow and tightly controlled bands, and photo luminescent material.
  • the light is delivered by a suitable conduit such as fibers (20) to the finger (30).
  • the light emerging from the finger is collected and delivered to a single detector (50) using a fiber or other suitable conduit (40).
  • a fiber or other suitable conduit for light of this wavelength an InGaAs photodiode is the preferred detector.
  • light “illumination”, “radiation” all refer to the light energy provided by a source, or sources, that is capable of delivering sufficient light at each of the desired wavelengths.
  • the finger is illuminated with the above narrowband sources simultaneously.
  • Light from multiple narrow band light sources (60) is delivered to the finger (80) by a suitable conduit (70).
  • the collected light would be delivered to a spectrometer (100) by a conduit (90), separated into its individual wavelengths using a grating (110) and then delivered to individual detectors or a detector array (120).
  • This approach reduces to some degree the light power per wavelength band that can be applied, but eliminates the error that exists in the first approach due to absorption changes in the finger which could effect each wavelength differently.
  • a light source which delivers continuous energy within the selected discrete wavelength range, for example 1100 to 1300nm, is used to illuminate the finger.
  • the collected light would be separated into its individual wavelengths using a grating and then delivered to individual detectors or a detector array.
  • This approach may further reduce the light power per wavelength band that can be further applied, but it offers the advantage that the system's measurement accuracy is not dependent on the wavelength stability of the light source.
  • the light source in this embodiment is described as being specific to the discrete wavelengths range. It is also possible to use for this purpose the same light source as is used to supply energy in the 500 to llOOnm wavelength region. A further alternative is to use the same light source as used to supply energy in the 500 to llOOnm wavelength region to supply energy to the discrete wavelength region and in addition boost the light intensity in the discrete wavelength region by a second source which supplies energy only in the discrete wavelength region.
  • the light source can emit light over a very wide band-width including light in the AV and NIR, for example a polychromatic source may be used.
  • a light source which is specific to this region is preferred.
  • the light from the light source passes first through a collimator, which is a collection of lenses that concentrate the light into a narrow parallel beam directed at the receptor.
  • the receptor is shaped to receive within it that part of the subject being measured, for example, a finger or ear of a human.
  • the receptor could be shaped so that the part of the human or animal, onto which the light is to be directed, is placed near the receptor rather than within the receptor.
  • the body part is in contact with the receptor, and light is directed onto and is dispersed by the body part.
  • the dispersed light is collected by lenses and directed through a slit to diffraction means.
  • the means for collecting the light after it is directed onto a receptor are fibre optics that transmit said light to diffraction means.
  • the collected light can be light that has passed through the body part or has reflected off the body part or a combination thereof.
  • the collected light is light that has passed through the parts of the subject.
  • the light from the grating disperses the light into its component wavelengths so that the light in the AV and NIR region falls along the length of a linear array detector.
  • the array is comprised of individual detectors a range of which respond to the AV and NIR region.
  • the array detector is electronically scanned by a microprocessor to measure intensity of light on each individual unit, or reflected from the tissue in the receptor.
  • the detector is connected to a microprocessor, producing an output spectrum, with the microprocessor analyzing the measurements from the linear array detector and the individual InGaAs detectors ultimately producing a result for each concentration level determined.
  • the results can be shown on a display and /or printed on a printer.
  • a keyboard allows a user to control the device, for example, to specify a particular constituent to be measured.
  • the timing and control may be activated by the microprocessor to control the device, for example, to determine number and timing of measurements.
  • the polychromatic light source can be a quartz-halogen or a tungsten-halogen bulb and is powered by a stabilized power source, for example, a DC power supply, or by a battery.
  • the linear array detector has at least ten elements, more preferably, 250- 300 units for measurement over the AV and NIR region.
  • a further advantage of a linear array detector is that it reduces the effect of pulses in the light signal waveform due to heartbeats because each diode is exposed to the pulsing light over exactly the same time interval.
  • the log of the inverse of these measurements is taken, that is, log 1/T and log 1/R, where T and R represent the transmittance and reflectance respectively.
  • a reference set of measurements is taken of the incident light, being the light generated in the device when no part of the subject is in contact with the receptor.
  • the absorbance is then calculated when a part of the subject, such as the finger, is in contact with the receptor as a ratio of measurements compared to the reference set of measurements.
  • the second derivative of measurements may be taken in order to reduce any variation in the result that will be caused by a change in path length for the light.
  • the noise level within the device may be reduced by a multiple scanning technique whereby the linear array detector takes a number of measurements and then average the results.
  • the linear array detector and discrete longer wavelength detectors are scanned many times for several repetitions and then averages the results.
  • the device and method can be used to measure concentration levels of various other constituents found within the blood of humans and animals, for example, amino acids, nitrogen, blood oxygenation, carbon dioxide, cortisol, creatine, creatinine, glucose, ketones, lipids, fat, urea, amino acids, fatty acids, glycosylated hemoglobin, cholesterol, alcohol, lactate, Ca ++ , K + , Cl " m HC ⁇ 3_ and HP ⁇ _, to name a few.
  • the method and device can be modified to measure several constituents simultaneously.
  • Example 1 Simulator A simulator has been developed to aid in the analysis of analyte measurement alternatives. It simulated all components of a system according to the present invention, namely light sources, light transmission means, optics, filters and detectors. It also simulated light loss through a body part based upon measured spectra of an analyte of interest as well as a number of interfering substances. The simulator developed combinations of body constituents on a random basis and then developed spectra of each combination. Examples of combinations developed are for example, for first set glucose 5 mM, total Hb 14 g/dL and 0 2 Sat 95% etc.; sample No. 2 glucose 7 mM; total
  • the specific wavelengths are: 1150, 1195, 1215, 1230, 1240 and 1250nm in the First region and 1595, 1610 and 1620nm in the Second region.
  • Individual wavelengths in the 1150 to 1250nm region as defined in the preferred embodiment set out above are created by passing the light through interference filters with bandwidths of approximately lOnm (Orion). Sequential illumination is achieved by mounting these filters onto a filter wheel (McPherson #941) (170) which is rotated by a Device Controller(McPherson #747) (180).
  • McPherson #941 (170
  • Device Controller Device Controller

Landscapes

  • Physics & Mathematics (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Spectroscopy & Molecular Physics (AREA)
  • Pathology (AREA)
  • General Health & Medical Sciences (AREA)
  • Surgery (AREA)
  • Public Health (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Medical Informatics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Optics & Photonics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Immunology (AREA)
  • Emergency Medicine (AREA)
  • Measurement Of The Respiration, Hearing Ability, Form, And Blood Characteristics Of Living Organisms (AREA)
  • Investigating Or Analysing Materials By Optical Means (AREA)

Abstract

L'invention porte sur un procédé de mesure de la concentration d'un constituant sanguin dans une partie (80) du corps d'un être vivant. Ce procédé consiste à irradier une partie du corps du patient avec un large spectre continu de rayonnement dans une gamme d'infrarouges adjacents et proches du spectre électromagnétique; recueillir la bande de rayonnement après irradiation de la partie du corps; disperser le rayonnement continu recueilli dans un spectre dispersé de longueurs d'onde de composants sur un détecteur (120) qui prend les mesures d'au moins un rayonnement émis ou réfléchi à partir du rayonnement recueilli; et transférer ces mesures vers le processeur (300); puis mesurer le même type d'absorbance ou réflectance par rapport à une ou plusieurs longueurs d'onde distinctes et utiliser ces mesures pour évaluer la concentration du constituant.
PCT/CA2000/001000 1999-08-31 2000-08-31 Procede de determination d'analytes au moyen d'un spectre en proche infrarouge, d'un spectre visible adjacent et de longueurs d'ondes distinctes de spectre en proche infrarouge WO2001016577A1 (fr)

Priority Applications (4)

Application Number Priority Date Filing Date Title
JP2001520083A JP2003508744A (ja) 1999-08-31 2000-08-31 Ｎｉｒ、隣接可視スペクトル及び離散ｎｉｒ波長を使用する分析物の量定方法
EP00955994A EP1214577A1 (fr) 1999-08-31 2000-08-31 Procede de determination d'analytes au moyen d'un spectre en proche infrarouge, d'un spectre visible adjacent et de longueurs d'ondes distinctes de spectre en proche infrarouge
CA002383725A CA2383725A1 (fr) 1999-08-31 2000-08-31 Procede de determination d'analytes au moyen d'un spectre en proche infrarouge, d'un spectre visible adjacent et de longueurs d'ondes distinctes de spectre en proche infrarouge
US10/070,187 US6741876B1 (en) 2000-08-31 2000-08-31 Method for determination of analytes using NIR, adjacent visible spectrum and discrete NIR wavelenths

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US15153799P 1999-08-31 1999-08-31
US60/151,537 1999-08-31

Publications (1)

Publication Number Publication Date
WO2001016577A1 true WO2001016577A1 (fr) 2001-03-08

Family

ID=22539212

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CA2000/001000 WO2001016577A1 (fr) 1999-08-31 2000-08-31 Procede de determination d'analytes au moyen d'un spectre en proche infrarouge, d'un spectre visible adjacent et de longueurs d'ondes distinctes de spectre en proche infrarouge

Country Status (4)

Country Link
EP (1) EP1214577A1 (fr)
JP (1) JP2003508744A (fr)
CA (1) CA2383725A1 (fr)
WO (1) WO2001016577A1 (fr)

Cited By (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002074162A1 (fr) * 2001-03-16 2002-09-26 Nellcor Puritan Bennett Incorporated Dispositif et procede pour controler des troubles de liquides biologiques et d'electrolyte
GB2382406A (en) * 2001-08-02 2003-05-28 Electrode Company Ltd Analytical apparatus
WO2003077761A1 (fr) * 2002-03-18 2003-09-25 Citizen Watch Co., Ltd. Analyseur de sang
WO2004097365A3 (fr) * 2003-04-30 2004-12-16 Univ Mcgill Methode et systeme pour mesurer la concentration de lactate in vivo
WO2006000911A1 (fr) * 2004-06-23 2006-01-05 Alec Blanchard Appareil d'analyse d'elements tissulaires et sanguins
US7239902B2 (en) 2001-03-16 2007-07-03 Nellor Puritan Bennett Incorporated Device and method for monitoring body fluid and electrolyte disorders
US7277741B2 (en) 2004-03-09 2007-10-02 Nellcor Puritan Bennett Incorporated Pulse oximetry motion artifact rejection using near infrared absorption by water
EP1897486A1 (fr) * 2006-09-11 2008-03-12 FOSS Analytical AB Dispositif de surveillance optique de substances sanguines à analyser
US7657292B2 (en) 2001-03-16 2010-02-02 Nellcor Puritan Bennett Llc Method for evaluating extracellular water concentration in tissue
ES2335565A1 (es) * 2008-09-26 2010-03-29 Hanscan Ip, B.V. Sistema optico, procedimiento y programa de ordenador para detectar la presencia de un elemento biologico vivo.
US7899506B2 (en) * 2002-11-04 2011-03-01 Tianjin Sunshine Optics Technolies Co. Ltd. Composite spectral measurement method and its spectral detection instrument
US8109882B2 (en) 2007-03-09 2012-02-07 Nellcor Puritan Bennett Llc System and method for venous pulsation detection using near infrared wavelengths
US8116852B2 (en) 2006-09-29 2012-02-14 Nellcor Puritan Bennett Llc System and method for detection of skin wounds and compartment syndromes
US8125623B2 (en) 2006-09-29 2012-02-28 Ottawa Hospital Research Institute Correlation technique for analysis of clinical condition
US8135448B2 (en) 2001-03-16 2012-03-13 Nellcor Puritan Bennett Llc Systems and methods to assess one or more body fluid metrics
US8175665B2 (en) 2007-03-09 2012-05-08 Nellcor Puritan Bennett Llc Method and apparatus for spectroscopic tissue analyte measurement
US8180419B2 (en) 2006-09-27 2012-05-15 Nellcor Puritan Bennett Llc Tissue hydration estimation by spectral absorption bandwidth measurement
US8280469B2 (en) 2007-03-09 2012-10-02 Nellcor Puritan Bennett Llc Method for detection of aberrant tissue spectra
US8346327B2 (en) 2007-03-09 2013-01-01 Covidien Lp Method for identification of sensor site by local skin spectrum data
US8357090B2 (en) 2007-03-09 2013-01-22 Covidien Lp Method and apparatus for estimating water reserves
US8690864B2 (en) 2007-03-09 2014-04-08 Covidien Lp System and method for controlling tissue treatment
US8965473B2 (en) 2005-09-29 2015-02-24 Covidien Lp Medical sensor for reducing motion artifacts and technique for using the same
US9895068B2 (en) 2008-06-30 2018-02-20 Covidien Lp Pulse oximeter with wait-time indication

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5303851B2 (ja) * 2007-04-03 2013-10-02 株式会社島津製作所 飲酒検知装置
JP5552819B2 (ja) * 2010-01-28 2014-07-16 ソニー株式会社 濃度測定装置
US20200178808A1 (en) * 2017-04-18 2020-06-11 Kowa Company, Ltd. Information processing method for calculating absorption spectrum of blood, information processing device and program
JP7182887B2 (ja) * 2018-03-27 2022-12-05 キヤノン株式会社 生体情報測定装置および生体情報測定方法

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996037259A1 (fr) * 1995-05-23 1996-11-28 Domjan Gyula Procede et appareil permettant l'evaluation rapide et non invasive des parametres de la composition sanguine
US5743262A (en) * 1995-06-07 1998-04-28 Masimo Corporation Blood glucose monitoring system
US5747806A (en) * 1996-02-02 1998-05-05 Instrumentation Metrics, Inc Method and apparatus for multi-spectral analysis in noninvasive nir spectroscopy
US5818048A (en) * 1992-07-15 1998-10-06 Optix Lp Rapid non-invasive optical analysis using broad bandpass spectral processing

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5672875A (en) * 1992-07-15 1997-09-30 Optix Lp Methods of minimizing scattering and improving tissue sampling in non-invasive testing and imaging

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5818048A (en) * 1992-07-15 1998-10-06 Optix Lp Rapid non-invasive optical analysis using broad bandpass spectral processing
WO1996037259A1 (fr) * 1995-05-23 1996-11-28 Domjan Gyula Procede et appareil permettant l'evaluation rapide et non invasive des parametres de la composition sanguine
US5743262A (en) * 1995-06-07 1998-04-28 Masimo Corporation Blood glucose monitoring system
US5747806A (en) * 1996-02-02 1998-05-05 Instrumentation Metrics, Inc Method and apparatus for multi-spectral analysis in noninvasive nir spectroscopy

Cited By (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8135448B2 (en) 2001-03-16 2012-03-13 Nellcor Puritan Bennett Llc Systems and methods to assess one or more body fluid metrics
US8457722B2 (en) 2001-03-16 2013-06-04 Covidien Lp Device and method for monitoring body fluid and electrolyte disorders
US8509866B2 (en) 2001-03-16 2013-08-13 Covidien Lp Device and method for monitoring body fluid and electrolyte disorders
US8229529B2 (en) 2001-03-16 2012-07-24 Nellcor Puritan Bennett Llc Device and method for monitoring body fluid and electrolyte disorders
WO2002074162A1 (fr) * 2001-03-16 2002-09-26 Nellcor Puritan Bennett Incorporated Dispositif et procede pour controler des troubles de liquides biologiques et d'electrolyte
US7657292B2 (en) 2001-03-16 2010-02-02 Nellcor Puritan Bennett Llc Method for evaluating extracellular water concentration in tissue
US7236811B2 (en) 2001-03-16 2007-06-26 Nellcor Puritan Bennett Incorporated Device and method for monitoring body fluid and electrolyte disorders
US7239902B2 (en) 2001-03-16 2007-07-03 Nellor Puritan Bennett Incorporated Device and method for monitoring body fluid and electrolyte disorders
GB2382406B (en) * 2001-08-02 2005-04-20 Electrode Company Ltd Analytical apparatus
GB2382406A (en) * 2001-08-02 2003-05-28 Electrode Company Ltd Analytical apparatus
WO2003077761A1 (fr) * 2002-03-18 2003-09-25 Citizen Watch Co., Ltd. Analyseur de sang
US7899506B2 (en) * 2002-11-04 2011-03-01 Tianjin Sunshine Optics Technolies Co. Ltd. Composite spectral measurement method and its spectral detection instrument
WO2004097365A3 (fr) * 2003-04-30 2004-12-16 Univ Mcgill Methode et systeme pour mesurer la concentration de lactate in vivo
US8195263B2 (en) 2004-03-09 2012-06-05 Nellcor Puritan Bennett Llc Pulse oximetry motion artifact rejection using near infrared absorption by water
US7277741B2 (en) 2004-03-09 2007-10-02 Nellcor Puritan Bennett Incorporated Pulse oximetry motion artifact rejection using near infrared absorption by water
US8175670B2 (en) 2004-03-09 2012-05-08 Nellcor Puritan Bennett Llc Pulse oximetry signal correction using near infrared absorption by water
WO2006000911A1 (fr) * 2004-06-23 2006-01-05 Alec Blanchard Appareil d'analyse d'elements tissulaires et sanguins
US8965473B2 (en) 2005-09-29 2015-02-24 Covidien Lp Medical sensor for reducing motion artifacts and technique for using the same
WO2008031756A1 (fr) * 2006-09-11 2008-03-20 Foss Analytical Ab Dispositif de surveillance d'analyte sanguin optique
EP1897486A1 (fr) * 2006-09-11 2008-03-12 FOSS Analytical AB Dispositif de surveillance optique de substances sanguines à analyser
US8180419B2 (en) 2006-09-27 2012-05-15 Nellcor Puritan Bennett Llc Tissue hydration estimation by spectral absorption bandwidth measurement
US8116852B2 (en) 2006-09-29 2012-02-14 Nellcor Puritan Bennett Llc System and method for detection of skin wounds and compartment syndromes
US8125623B2 (en) 2006-09-29 2012-02-28 Ottawa Hospital Research Institute Correlation technique for analysis of clinical condition
US8175665B2 (en) 2007-03-09 2012-05-08 Nellcor Puritan Bennett Llc Method and apparatus for spectroscopic tissue analyte measurement
US8280469B2 (en) 2007-03-09 2012-10-02 Nellcor Puritan Bennett Llc Method for detection of aberrant tissue spectra
US8346327B2 (en) 2007-03-09 2013-01-01 Covidien Lp Method for identification of sensor site by local skin spectrum data
US8357090B2 (en) 2007-03-09 2013-01-22 Covidien Lp Method and apparatus for estimating water reserves
US8109882B2 (en) 2007-03-09 2012-02-07 Nellcor Puritan Bennett Llc System and method for venous pulsation detection using near infrared wavelengths
US8690864B2 (en) 2007-03-09 2014-04-08 Covidien Lp System and method for controlling tissue treatment
US9895068B2 (en) 2008-06-30 2018-02-20 Covidien Lp Pulse oximeter with wait-time indication
WO2010034848A1 (fr) * 2008-09-26 2010-04-01 Hanscan Ip B.V. Système optique, procédé et programme informatique pour détecter la présence d'un élément biologique vivant
US8766189B2 (en) 2008-09-26 2014-07-01 Hanscan Ip B.V. Optical system, method and computer program for detecting the presence of a living biological organism
ES2335565A1 (es) * 2008-09-26 2010-03-29 Hanscan Ip, B.V. Sistema optico, procedimiento y programa de ordenador para detectar la presencia de un elemento biologico vivo.

Also Published As

Publication number Publication date
EP1214577A1 (fr) 2002-06-19
CA2383725A1 (fr) 2001-03-08
JP2003508744A (ja) 2003-03-04

Similar Documents

Publication Publication Date Title
US6741876B1 (en) Method for determination of analytes using NIR, adjacent visible spectrum and discrete NIR wavelenths
EP1214577A1 (fr) Procede de determination d'analytes au moyen d'un spectre en proche infrarouge, d'un spectre visible adjacent et de longueurs d'ondes distinctes de spectre en proche infrarouge
EP0630203B1 (fr) Dispositif non invasif et methode pour determiner les concentrations de differents composants du sang ou des tissus
US6741875B1 (en) Method for determination of analytes using near infrared, adjacent visible spectrum and an array of longer near infrared wavelengths
US7343185B2 (en) Measurement of body compounds
US5361758A (en) Method and device for measuring concentration levels of blood constituents non-invasively
EP1478265B1 (fr) Spectraphotometrie a impulsion active
US8406839B2 (en) Method and apparatus for determining blood analytes
WO2001016578A1 (fr) Procede de determination d'analytes au moyen d'un spectre visible adjacent, a infrarouge proche et reseau de longueurs d'onde plus longues a infrarouge proche
KR100893432B1 (ko) 조직 샘플 중의 표적 분석 물질 특성의 비침습적 측정방법 및 이를 위한 장치
US5137023A (en) Method and apparatus for monitoring blood analytes noninvasively by pulsatile photoplethysmography
US5086229A (en) Non-invasive measurement of blood glucose
AU749033B2 (en) Apparatus and method for noninvasive glucose measurement
JP2002310908A (ja) 非侵襲性赤外分光法における多重スペクトル分析のための方法および装置
JP2000515778A (ja) 体液成分レベルの生体内測定および制御のための埋込可能センサーおよびシステム
JP2004279427A (ja) 目的物の成分濃度測定方法及び装置
US8523785B2 (en) Method and apparatus for measuring analytes
Liu et al. Next step of non-invasive glucose monitor by NIR technique from the well controlled measuring condition and results
EP2319394A1 (fr) Dispositif et procédénon invasive pour la surveillance des analytes contenus dans des échantillons biologiques

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): CA JP US

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
ENP Entry into the national phase

Ref country code: JP

Ref document number: 2001 520083

Kind code of ref document: A

Format of ref document f/p: F

WWE Wipo information: entry into national phase

Ref document number: 2383725

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2000955994

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2000955994

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 10070187

Country of ref document: US

WWW Wipo information: withdrawn in national office

Ref document number: 2000955994

Country of ref document: EP